title: Treatment of Brucella endocarditis: 15 years of clinical and surgical experience.
abstract: BACKGROUND
  Brucella endocarditis is a life-threatening complication of human brucellosis. In this study, our aim was to evaluate the effects of combined medical and surgical treatment in the midterm to long term.
  
  
  METHODS
  We retrospectively analyzed 13 patients (mean age 44 +/- 18 years; 8 males) who were operated on from January 1993 to June 2009. Duke criteria were used for the diagnosis of endocarditis. The primary endpoint was defined as the overall mortality and readmission to the hospital during early and late follow-up periods. The other collected data included baseline and follow-up clinical findings, along with echocardiographic and laboratory measurements.
  
  
  RESULTS
  No patients died in the early period (up to 1 month) and 2 patients (15.3%) died during the late follow-up period. Aortic valve disease was observed in 11 of 13 patients (85%). The most commonly performed procedure was aortic valve replacement (10 of 13 patients; 77%) during a mean follow-up period of 95 +/- 60 months (range, 10 to 184; median, 74).
  
  
  CONCLUSIONS
  For Brucella endocarditis, perioperative antibiotic therapy combined with surgical treatment (prosthetic valve replacement) has satisfactory results and increases the quality of life in the long-term follow-up.
authors.affiliation: Department of Cardiovascular Surgery, Kartal Kosuyolu Heart and Research Hospital, Istanbul, Turkey. sasmazel@yahoo.com
authors.forename: Ahmet
authors.initials: A
authors.lastname: Sasmazel
authors.forename: Ayse
authors.initials: A
authors.lastname: Baysal
authors.forename: Ali
authors.initials: A
authors.lastname: Fedakar
authors.forename: Onursal
authors.initials: O
authors.lastname: Buğra
authors.forename: Mehmet
authors.initials: M
authors.lastname: Ozkokeli
authors.forename: Fuat
authors.initials: F
authors.lastname: Büyükbayrak
authors.forename: Cüneyt
authors.initials: C
authors.lastname: Keleş
authors.forename: Sinan
authors.initials: S
authors.lastname: Göçer
authors.forename: Hasan
authors.initials: H
authors.lastname: Sunar
authors.forename: Rahmi
authors.initials: R
authors.lastname: Zeybek
mesh_terms: D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D002006:Brucellosis / Q000175:diagnosis / Q000401:mortality / Q000628:therapy*; D015331:Cohort Studies; D003131:Combined Modality Therapy; D004359:Drug Therapy, Combination; D004697:Endocarditis, Bacterial / Q000000981:diagnostic imaging / Q000401:mortality / Q000628:therapy*; D005260:Female; D005500:Follow-Up Studies; D006349:Heart Valve Diseases / Q000000981:diagnostic imaging / Q000382:microbiology / Q000401:mortality / Q000628:therapy*; D006350:Heart Valve Prosthesis; D019918:Heart Valve Prosthesis Implantation / Q000379:methods*; D006801:Humans; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D018570:Risk Assessment; D012720:Severity of Illness Index; D015996:Survival Rate; D016896:Treatment Outcome; D014463:Ultrasonography; D055815:Young Adult
chemical_list: D000900:Anti-Bacterial Agents